AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05087862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular local anesthetic infiltration of the hip
Description: Intraoperatively, 60 mL of adrenalized 0.25% bupivacaine plus ketorolac 30 mg will be infiltrated by the surgeon.
Study NCT05124561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
Description: Nebulized inhalation through the mouth
Study NCT05124561 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebulized inhalation through the mouth
Study NCT05697926 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is a preclinical study. No intervention will be performed.
Study NCT05611450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: disease self-management application
Description: The mHealth application provide disease self-management knowledge and skills and also has the functions of level of skin toxicity warning, uploading photos of skin toxicity, and interacting with healthcare professionals.
Study NCT05611450 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: disease self-management application
Description: The mHealth application provide disease self-management knowledge and skills and also has the functions of level of skin toxicity warning, uploading photos of skin toxicity, and interacting with healthcare professionals.
Study NCT04991220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoxygenation
Description: Taking 8 deep breaths at 10 l/min of 100% oxygen for 1 minute with forced inspiration for pre-oxygenation
Study NCT06373666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spatz4 Adjustable Balloon System
Description: Implantation of Spatz4 Adjustable Balloon system for weight loss treatment for Overweight and Obese patients and Adjustment of the balloon volume at week 16
Study NCT06528626 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: rapid HIV and HCV serological tests
Description: In the standard of care branch (SOC), the health personnel will ask people a series of questions to identify the HIV risk exposition, and also they will be provided pop-up computer alerts of HIV indicator conditions in the electronic medical record, moreover HIV and HCV serological tests will be carried out in the reference laboratory, while in the intervention branch in addition to the SOC, a SQ-R\&IC of HIV and HCV will be made available to the HC population, through a quick response (QR) code, as well as HIV and HCV RT.
Study NCT05311514 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic platelet lysate eye drops
Description: Eye drops
Study NCT05311514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic platelet lysate eye drops
Description: Eye drops
Study NCT05800899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Interviewing
Description: Standard non-adapted brief motivational interviewing based on motivational interviewing.
Study NCT05800899 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally adaptation brief motivational interviewing
Description: culturally adapted brief motivational interviewing based on motivational interviewing.
Study NCT04908150 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core training
Description: A total of 12 sessions were carried out, which lasted for 4 weeks, with a frequency of 3 sessions/ week. The duration of each session was 11 minutes 30 seconds. The working time of each exercise was 30 seconds with a 5 seconds rest between exercises, meaning that each exercise cycle lasted for 2.50 seconds. Three exercise cycles were performed with a 90 seconds rest between each one of them
Study NCT04908150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core training
Description: A total of 12 sessions were carried out, which lasted for 4 weeks, with a frequency of 3 sessions/ week. The duration of each session was 11 minutes 30 seconds. The working time of each exercise was 30 seconds with a 5 seconds rest between exercises, meaning that each exercise cycle lasted for 2.50 seconds. Three exercise cycles were performed with a 90 seconds rest between each one of them
Study NCT04794348 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma (FFP)
Description: Autologous units of fresh frozen plasma collected from the subject by plasmapheresis
Study NCT04794348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Freeze Dried Plasma (FDP)
Description: Autologous units of freeze dried plasma manufactured from plasma collected from the subject by plasmapheresis
Study NCT06068374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Break of sedentary behavior with dual task
Description: Patients will interrupt sedentary behavior performing walking and cognitive activities simultaneously
Study NCT06068374 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Break of sedentary behavior with walking
Description: Patients will interrupt sedentary behavior performing walking
Study NCT04896801 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR-guided RT
Description: The dose to the planning target volume (PTV) is 36 Gy (5 x 7.2 Gy) prescribed on the 90% isodose line. The clinical target volume (CTV) is receiving 40 Gy (5 x 8 Gy = 100%). A simultaneous integrated boost (SIB) up to a total dose of 42 Gy (5 x 8.4 Gy = 105%) is delivered to the gross tumor volume (GTV), if present. In addition, relative sparing of the urethra will be applied by avoiding hotspots (V40 Gy \< 1cc) in the urethra. Baseline and adapted treatment plans are generated using intensity-modulated RT
Study NCT05161871 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cathodal transcranial direct current stimulation
Description: The cathodal transcranial direct current stimulation protocol will consist in five daily sessions, each lasting 20 min. The montage will provide a bilateral stimulation on occipital areas, with the reference anodal electrodes positioned on the M1 areas. The stimulation will be applied via 4 conductive-rubber square electrodes (5x5 cm) placed in sponges saturated with high conductivity gel and connected to a battery-operated stimulator system. Direct current with maximal intensity of 1.5 mA with be provided for 20 minutes.
Study NCT05161871 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cathodal transcranial direct current stimulation
Description: Sham stimulation will be performed by the same protocol as active stimulation; however, the device will be switched off 30 seconds after the beginning of stimulation. This way, the patient will experience the same sensations as with active stimulation without receiving actual stimulation.
Study NCT05008705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Patients will receive diary 2 doses of the protein supplement
Study NCT05008705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrostimulation.
Description: Patients will receive diary sessions of neuromuscular electrostimulation.
Study NCT05008705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (isocaloric supplement)
Description: Patients will receive diary 2 doses of the isocaloric supplement
Study NCT05008705 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham for neuromuscular electrostimulation.
Description: Patients will not receive neuromuscular electrostimulation.
Study NCT04759482 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: polysomnography
Description: Polysomnography consisted in recording sleep parameters during one night, using a non-invasive multi-channels device, including respiratory sensors, electrocardiogram and electroencephalogram
Study NCT04727840 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sodium Zirconium Cyclosilicate Oral Product
Description: Sodium zirconium cyclosilicate (SZC), a non-absorbed cation exchanger, selectively binds potassium in the intestine. SZC is in a powder form and will be provided to patients in packets containing 5g or 10gm of the medication. Participants will mix the contents of one packet with water (about 45mL). The drink should be stirred and drank immediately. If powder remains in the glass, then water should be added and the remainder of the drink should be consumed. Other medications should be taken 2 hours before or after SZC.~At Day 0 and Day 1, participants will be taking SZC at 10gm three times a day. A serum potassium will be checked on Day 2; if serum potassium is \<5.1mEq/L, then the dose will be decreased to the maintenance dose of 5gm per day. At each serum potassium checks, the medication dosage will be adjusted accordingly.
Study NCT05324579 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral testing during neuronal recordings
Description: Participants undergoing clinically planned neurosurgical procedures will undergo single-neuronal recordings as they perform brief behavioral tasks.
Study NCT05488054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Patients will undergo physical therapy following surgical intervention
Study NCT05488054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monitored Work-out
Description: Healthy volunteers will undergo a monitored workout for comparison of data
Study NCT05488054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moxy Oxygen Sensor Device
Description: Individuals will wear a Moxy sensor device during workouts to monitor oxygen and hemoglobin levels in their muscles
Study NCT04870944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04870944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspirate
Study NCT04870944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT04870944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT04870944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACT Complex-targeting Curaxin CBL0137
Description: Given IV
Study NCT05919940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: additional substitution of protein
Description: Day one (admission) no nutrition is applied.~Protein target is increased as follows:~* to a level of 1,2g/kg/d on day 1 after ICU admission~* to a level of 1,4g/kg/d on day 2 after ICU admission~* to a level of 1,6g/kg/d on day 3 after ICU admission~* to a level of 1,8g/kg/d on day 4 after ICU admission~* to a level of 2,0g/kg/d from day 5 onwoards~Additional protein is given within 2 hours after mobilization respectively:~* to 0,125g/kg/d on day 1 after ICU admission~* to 0,2g/kg/d on day 2 after ICU admission~* to 0,25g/kg/d on day 3 after ICU admission~* to 0,3g/kg/d from day 4 after ICU admission onwoards
Study NCT05919940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: twice daily 60 minutes till day 28 or ICU discharge
Study NCT05919940 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Mobilization
Description: at least 20 minutes a day following the SOMS concept. Duration: till 28 day or ICU discharge
Study NCT05942716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of a PET radiotracer
Description: A highly selective 5-HT2A receptor ligand (\[18F\]-altanserin) will be injected to patients before each PET scan. The IV injection in the arm (via a catheter) will be performed in continue during a period of 2 hours in the imaging centre (CERMEP) before the acquisition. The dose will be 2,6 MBq/kg +/- 10 % depending the prescription of the nuclear medicine.~Patients will be evaluated twice, one time free of neuroleptic treatment and a second time during stable chronic treatment by neuroleptic.
Study NCT06205472 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant SIB radiotherapy
Description: Eligibility patients will receive IMRT or VMAT to high risk area of tumor bed and tumor bed. The prescription dose to 95% GTVtb boost was planned at 55-60Gy, with PTV 45-50Gy, in 23-25 fractions,mainly depending on the dose constraints of OARs.
Study NCT06112301 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IdentiClone Dx IGH (IC IGH Dx) Assay
Description: The IdentiClone Dx IGH Assay is an in vitro diagnostic product intended for qualitative, capillary electrophoresis based-detection of clonality in immunoglobulin heavy chain gene rearrangements (IGH) in peripheral blood specimens as an adjunctive method for the diagnosis of B-cell lymphoproliferative disease
Study NCT06506110 — intervention group
Intervention type: OTHER
Intervention: Retrieving of retrospective data from Epic
Description: Retrospective data from Epic will be extracted to determine the Patient Acceptable Symptom State (PASS) for the numeric rating scale (NRS) pain score in the first 48 hours after surgery in patients who received intravenous Patient Controlled Analgesia.
Study NCT05344027 — intervention group
Intervention type: DRUG
Intervention: Mitotane
Description: Individuals within the intervention group were on mitotane therapy as part of their ACC treatment.
Study NCT05451472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: thyroid function tests
Description: Thyroid function tests:thyroid stimulating hormone (TSH), total thyroxine (T4), free thyroxine (FT4), total triiodothyronine (T3), and free triiodothyronine (FT3)
Study NCT05451472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: complete blood count
Description: complete blood count
Study NCT05451472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum creatinine
Description: serum creatinine
Study NCT05451472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood urea
Description: blood urea
Study NCT05451472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum electrolyte
Description: serum electrolyte
Study NCT05451472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum calcium
Description: serum calcium
Study NCT05451472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: serum phosphorus
Description: serum phosphorus
Study NCT05451472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: parathyroid hormone level
Description: parathyroid hormone level
Study NCT05451472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: liver function test
Description: ALT_AST_Total biliruin_total protein _serum albumin
Study NCT05451472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: arterial blood gases
Description: PH_PCO2_PO2_HCO3_base deficit
Study NCT05451472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: complete urine analysis
Description: complete urine analysis
Study NCT05000372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-grazytracer
Description: 68Ga-grazytracer PET/CT: after intravenous injection of 2.96-3.7 MBq/kg body weight of quality-controlled 68Ga-grazytracer, a Biograph mCT Flow 64 scanner or Total-body PET/CT uEXPLORER scanner will be applied, and the scan range will be from the top of the head to 1/3 of the upper thigh.
Study NCT06438198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-specified switch from controlled to assisted ventilation when PaO2/FiO2-ratio > 200 mmHg
Description: A pre-specified switch from controlled to assisted ventilation will be initiated when PaO2/FiO2-ratio > 200 mmHg. The moment of switch is pre-specified but patient management and ventilator settings are up to the clinical team. Switch is complete when the patient triggers all breaths spontaneously. Switch success is defined if patient reaches 72 hours on assisted ventilation. Switch failure is defined if patient switches back to controlled ventilation for more than 2 hours before 72 hours.
Study NCT05320406 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Undergo radiation therapy
Study NCT05320406 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Undergo radiation therapy
Study NCT05320406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Given IM or SC
Study NCT05320406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Given PO
Study NCT05198258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation strategy - experimental group
Description: On-line theoretical education and three hours of practical training by the project leaders. Contact with the project team via e-mail, phone and on-line repetition of the education for remaining of the clinical examination, neck-specific program and the progression of exercises.
Study NCT05198258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation - control group
Description: Physiotherapists in the control group will receive the same theoretical and practical training as the experimental group but without repetition of the education or support from the research team.
Study NCT04758858 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Insulin treatment optimization with participant's usual diet
Description: Two weeks before the intervention phase, insulin dose optimization and revision of participants' knowledge on carbohydrates counting, hypo- and hyperglycemia prevention and treatment will be done with a nurse and a dietitian under a physician's supervision. Once to twice a week, participants will be contacted to review if glucose values are in target.
Study NCT04758858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insulin treatment optimization with participant's usual diet
Description: Two weeks before the intervention phase, insulin dose optimization and revision of participants' knowledge on carbohydrates counting, hypo- and hyperglycemia prevention and treatment will be done with a nurse and a dietitian under a physician's supervision. Once to twice a week, participants will be contacted to review if glucose values are in target.
Study NCT04758858 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Abbott's FreeStyle Libre
Description: During the whole trial, blood glucose will be assessed by intermittent scanning Continuous Glucose Monitors (isCGM; Abbott's Freestyle-Libre glucose sensor). Participants will be asked to record or download, in their Freestyle Libre reader or in their insulin pump, their insulin doses being injected each day.
Study NCT04758858 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott's FreeStyle Libre
Description: During the whole trial, blood glucose will be assessed by intermittent scanning Continuous Glucose Monitors (isCGM; Abbott's Freestyle-Libre glucose sensor). Participants will be asked to record or download, in their Freestyle Libre reader or in their insulin pump, their insulin doses being injected each day.
Study NCT04758858 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Three-day food journal
Description: Two weeks before the intervention phase, participants will be asked to complete a 3-day food journal, using the Keenoa mobile application, with carbohydrates (CHO) content of food and blood glucose measures to optimize their insulin doses. Analysis of the food journal will allow us to quantify the participants' usual diet.
Study NCT04758858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Three-day food journal
Description: Two weeks before the intervention phase, participants will be asked to complete a 3-day food journal, using the Keenoa mobile application, with carbohydrates (CHO) content of food and blood glucose measures to optimize their insulin doses. Analysis of the food journal will allow us to quantify the participants' usual diet.
Study NCT04758858 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Medical visit
Description: During visit 1, a short medical interview will be done to establish if the subject is eligible to participate in the study. A list of current medications, presence of complications, as well as comorbidities associated with their diabetes will be collected in their medical file during the visit with the endocrinologist.
Study NCT04758858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical visit
Description: During visit 1, a short medical interview will be done to establish if the subject is eligible to participate in the study. A list of current medications, presence of complications, as well as comorbidities associated with their diabetes will be collected in their medical file during the visit with the endocrinologist.
Study NCT04758858 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Blood pressure measurements
Description: Blood pressure (systolic and diastolic blood pressure) will be measured during all visits (visits 1 to 4).
Study NCT04758858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure measurements
Description: Blood pressure (systolic and diastolic blood pressure) will be measured during all visits (visits 1 to 4).
Study NCT04758858 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anthropometric parameters measurements
Description: Weight, height, BMI and waist circumference will be measured during all visits (visits 1 to 4).
Study NCT04758858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anthropometric parameters measurements
Description: Weight, height, BMI and waist circumference will be measured during all visits (visits 1 to 4).